22nd Century Group (NASDAQ:XXII) Cut to Sell at StockNews.com

StockNews.com downgraded shares of 22nd Century Group (NASDAQ:XXII) from a hold rating to a sell rating in a report released on Tuesday morning.

22nd Century Group Trading Up 5.5 %

XXII opened at $5.60 on Tuesday. The company has a market cap of $3.10 million, a P/E ratio of -0.25 and a beta of 1.50. 22nd Century Group has a one year low of $3.90 and a one year high of $581.85. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.93 and a current ratio of 1.09. The business’s 50-day simple moving average is $10.83 and its 200-day simple moving average is $45.88.

22nd Century Group (NASDAQ:XXII) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($72.90) earnings per share (EPS) for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 144.09%. The business had revenue of $5.95 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in 22nd Century Group stock. Anson Funds Management LP bought a new stake in 22nd Century Group, Inc. (NASDAQ:XXII) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,140,452 shares of the biotechnology company’s stock, valued at approximately $691,000. Anson Funds Management LP owned approximately 6.77% of 22nd Century Group as of its most recent filing with the SEC. Institutional investors and hedge funds own 18.06% of the company’s stock.

22nd Century Group Company Profile

22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.